In this episode, we’re joined by Dr. Madeline Lancaster, a leading scientist whose innovative work in cerebral organoids, or "mini brains," has transformed our understanding of human brain development. After earning her PhD in Biomedical Sciences at UC San Diego, she completed a postdoctoral fellowship at the Institute of Molecular Biotechnology in Vienna, where she developed groundbreaking methods to model neurodevelopmental disorders like microcephaly.

Now a Group Leader at the MRC Laboratory of Molecular Biology in Cambridge, Dr. Lancaster continues to pioneer research in stem cell biology and neuroscience. In this episode, we’ll explore her career journey, pivotal discoveries, and insights into the future of biomedical science.

Hosts: Laura Ryan and Laura Lungu

Link to YouTube video: https://www.youtube.com/watch?v=JDdzcBBektU

Today, we’re excited to welcome Michael Anstey to Gravity Encounters, Partner at Cambridge Innovation Capital. With a career that bridges science, entrepreneurship, and venture capital, Mike has been a driving force behind some of biotech’s most exciting innovations. From earning a DPhil in neurobiology at Oxford to co-founding a company whilst working at BCG, and guiding startups like Bicycle Therapeutics, his journey is a testament to the power of bold ideas and calculated risks. As a leader at Cambridge Innovation Capital and co-founder of Innovate Cambridge, Mike is shaping the future of biotech and the innovation ecosystem. Today, we’ll dive into the moments, challenges, and insights that have defined his extraordinary path.

Today, we’re joined by Mark O'Connor, a pioneer in the field of oncology R&D, whose work has significantly impacted the way we approach cancer treatment. With over 30 years of experience, our guest serves as Chief Scientist in AstraZeneca’s Oncology R&D division, providing scientific leadership to a team of more than 150 researchers. Specializing in DNA damage response (DDR) biology, he has been instrumental in the discovery and development of groundbreaking cancer therapies, including olaparib (Lynparza), the first-in-class PARP inhibitor approved for clinical use.

In this episode, we delve into his remarkable journey—from earning a Ph.D. in Biochemistry at Bristol University to conducting postdoctoral research in Singapore, and ultimately leading the development of AstraZeneca’s industry-leading DDR pipeline. He shares insights from his time at the Cambridge start-up KuDOS, which laid the foundation for the success of Lynparza. We also discuss his commitment to building global collaborations and driving innovation that translates scientific discoveries into life-changing medicines for patients.

Tune in for a fascinating conversation about scientific leadership, the future of oncology R&D, and how a lifelong passion for advancing cancer care has shaped his life and career.